Ascentage Pharma Group International (FRA:36X)

Market Cap	1.47B -17.8%
Revenue (ttm)	69.91M -41.5%
Net Income	-151.33M
EPS	-0.42
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.840
Previous Close	3.960
Day's Range	3.840 - 3.860
52-Week Range	0.845 - 10.000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 3, 2026

About FRA:36X

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 767
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 36X

Financial Performance

In 2025, FRA:36X's revenue was 574.12 million, a decrease of -41.46% compared to the previous year's 980.65 million. Losses were -1.24 billion, 206.5% more than in 2024.

Financial numbers in CNY